A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- Registration Number
- NCT03153111
- Lead Sponsor
- Actelion
- Brief Summary
This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease.
The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 143
- Signs or symptoms of Heart Failure (HF) (NYHA FC I I and II I ) requiring treatment with at least one oral diuretic (any type)
- Left ventricular ejection fraction (LVEF) ≥ 40% (by echocardiography at Screening)
- Structural heart disease consistent with heart failure with preserved ejection fraction (HFpEF) established by echocardiography at Screening
- Elevated NT-proBNP
- Pulmonary vascular disease or right ventricular dysfunction
- Any prior valid measurement of LVEF < 40%. An echocardiogram is considered valid if its quality is sufficient to allow accurate assessment of LVEF and if it is reflective of the true status of the subject
- Cardiovascular co-morbidities (e.g., significant unrepaired structural valvular heart disease; acute coronary syndrome, coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) within 3 months of Screening; uncontrolled heart rate from atrial fibrillation or atrial flutter, history of serious life-threatening or hemodynamically significant arrhythmia; history of or anticipated heart transplant or ventricular assist device implantation, etc)
- Systolic blood pressure (SBP) ≥ 180 mmHg, or diastolic blood pressure (DBP) ≥ 110 mmHg during Screening
- Hemoglobin < 100g/L (< 10 g/dl) at Screening
- Significant parenchymal lung disease (e.g., severe COPD, moderate or severe restrictive lung disease, diffuse interstitial fibrosis or alveolitis, pulmonary thromboembolism)
- Severe renal dysfunction with an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min per 1.73 m2
- Severe hepatic impairment, e.g., Child Pugh Class C
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks. Macitentan Macitentan Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
- Primary Outcome Measures
Name Time Method Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 Week 24 Percent of baseline NT-proBNP assessed at Week 24 was reported. Percent of baseline is calculated as the ratio of the Week 24 NT-proBNP value over baseline value, expressed in percentage. NT-proBNP is one of the best established cardiovascular response markers among all available surrogates in heart failure (HF).
- Secondary Outcome Measures
Name Time Method Change From Baseline to Week 24 in Accelerometer-assessed Proportion of Time Spent in Light to Vigourous Physical Activity Baseline to Week 24 Physical activity is assessed by accelerometer as the proportion of time spent in light to vigorous physical activity based on a threshold of greater than (\>)100 activity counts per minute and expressed as change from baseline to Week 24.
Number of Participants With Worsening of Heart Failure (WHF) Events Over 52 Weeks Weeks 16, 24, 36, 52 Number of participants with WHF events were reported. A WHF event includes HF death, hospitalization for WHF or an urgent visit for WHF.
Change From Baseline to Week 24 in the Clinical Summary Score Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ) Score Baseline to Week 24 The KCCQ is a validated health related quality of life measure for heart failure. The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Clinical summary score is one of the quality of life variable of interest derived from KCCQ. Clinical summary score is the mean of domains: physical limitations score (6 items) and total symptom score (2 items \[symptoms frequency and symptom burden\]). The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status.
Trial Locations
- Locations (95)
Mayo Clinic Arizona
🇺🇸Phoenix, Arizona, United States
Cedars Sinai Heart Institute
🇺🇸Beverly Hills, California, United States
Sharp Memorial Hospital
🇺🇸San Diego, California, United States
Harbor Ucla Medical Center
🇺🇸Torrance, California, United States
South Denver Cardiology Associates PC
🇺🇸Littleton, Colorado, United States
Northwestern University Feinberg School of Medicine
🇺🇸Chicago, Illinois, United States
University Of Iowa - Hospitals & Clinics
🇺🇸Iowa City, Iowa, United States
University of Maryland
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Washington University School Of Medicine
🇺🇸Saint Louis, Missouri, United States
Scroll for more (85 remaining)Mayo Clinic Arizona🇺🇸Phoenix, Arizona, United States